Metabolic spectrum of liver failure in type 2 diabetes and obesity: from NAFLD to NASH to HCC

Cited 0 time in scopus
Metadata Downloads
Metabolic spectrum of liver failure in type 2 diabetes and obesity: from NAFLD to NASH to HCC
Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon KimKwang-Hee BaeKyoung-Jin Oh
Bibliographic Citation
International Journal of Molecular Sciences, vol. 22, no. 9, pp. 4495-4495
Publication Year
Liver disease is the spectrum of liver damage ranging from simple steatosis called as nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Clinically, NAFLD and type 2 diabetes coexist. Type 2 diabetes contributes to biological processes driving the severity of NAFLD, the primary cause for development of chronic liver diseases. In the last 20 years, the rate of non-viral NAFLD/NASH-derived HCC has been increasing rapidly. As there are currently no suitable drugs for treatment of NAFLD and NASH, a class of thiazolidinediones (TZDs) drugs for the treatment of type 2 diabetes is sometimes used to improve liver failure despite the risk of side effects. Therefore, diagnosis, prevention, and treatment of the development and progression of NAFLD and NASH are important issues. In this review, we will discuss the pathogenesis of NAFLD/NASH and NAFLD/NASH-derived HCC and the current promising pharmacological therapies of NAFLD/NASH. Further, we will provide insights into “adipose-derived adipokines” and “liver-derived hepatokines” as diagnostic and therapeutic targets from NAFLD to HCC.
Non-alcholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)Hepatocellular carcinoma (HCC)Type 2 diabetesObesityAdipokinesHepatokines
Appears in Collections:
Division of Biomedical Research > Metabolic Regulation Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.